Biologic Therapies in Chronic Rhinosinusitis with Nasal Polyps: A Narrative Review of Current Approaches and Latin American Perspectives

1. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464. https://doi.org/10.4193/Rhin20.600

2. Castillo-Bustamante M, Tapia L, Ricardo MA, Cuevas SM. Epidemiología de la poliposis nasal. Fronteras Med. 2018;13(1):18-21.

3. Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61(11):1280-9. https://doi.org/10.1111/j.1398-9995.2006.01225.x

4. Shen Y, Zhang N, Yang Y, Hong S, Bachert C. Local immunoglobulin E in nasal polyps: Role and modulation. Front Immunol. 2022;13:961503. https://doi.org/10.3389/fimmu.2022.961503

5. Stevens WW, Lee RJ, Schleimer RP, Cohen NA. Chronic rhinosinusitis pathogenesis. J Allergy Clin Immunol. 2015;136(6):1442-53. https://doi.org/10.1016/j.jaci.2015.10.009

6. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1-12. https://doi.org/10.4193/Rhino12.000

7. Kohanski MA, Toskala E, Kennedy DW. Evolution in the surgical management of chronic rhinosinusitis: Current indications and pitfalls. J Allergy Clin Immunol. 2018;141(5):1561-9. https://doi.org/10.1016/j.jaci.2018.03.003

8. Agache I, Song Y, Alonso-Coello P, Vogel Y, Rocha C, Solà I, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review. Allergy. 2021;76(8):2337-53. https://doi.org/10.1111/all.14809

9. Nakagome K, Nagata M. The Possible roles of IL-4/IL-13 in the Development of Eosinophil-Predominant severe asthma. Biomolecules. 2024;14(5):546. https://doi.org/10.3390/biom14050546

10. De Schryver E, Devuyst L, Derycke L, Dullaers M, Van Zele T, Bachert C, et al. Local immunoglobulin e in the nasal mucosa: clinical implications. Allergy Asthma Immunol Res. 2015;7(4):321-31. https://doi.org/10.4168/aair.2015.7.4.321

11. Bachert C, Marple B, Hosemann W, Cavaliere C, Wen W, Zhang N. Endotypes of chronic rhinosinusitis with nasal polyps: Pathology and possible therapeutic implications. J Allergy Clin Immunol Pract. 2020;8(5):1514-9. https://doi.org/10.1016/j.jaip.2020.03.007

12. Workman AD, Kohanski MA, Cohen NA. Biomarkers in chronic rhinosinusitis with nasal polyps. Immunol Allergy Clin North Am. 2018;38(4):679-92. https://doi.org/10.1016/j.iac.2018.06.006

13. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M, et al. Clinical practice guideline (update): Adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1-39. https://doi.org/10.1177/0194599815572097

14. Soler ZM, Jones R, Le P, Rudmik L, Mattos JL, Nguyen SA, et al. Sino-Nasal outcome test-22 outcomes after sinus surgery: A systematic review and meta-analysis. Laryngoscope. 2018;128(3):581-92. https://doi.org/10.1002/lary.27008

15. Patel ZM, Thamboo A, Rudmik L, Nayak JV, Smith TL, Hwang PH. Surgical therapy vs continued medical therapy for medically refractory chronic rhinosinusitis: A systematic review and meta-analysis. Int Forum Allergy Rhinol. 2017;7(2):119-27. https://doi.org/10.1002/alr.21872

16. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-50. https://doi.org/10.1016/S0140-6736(19)31881-1

17. Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(3):725-39. https://doi.org/10.1016/j.jaci.2020.01.020

18. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-96. https://doi.org/10.1056/NEJMoa1804092

19. Bachert C, Khan AH, Fokkens WJ, Hopkins C, Gevaert P, Han JK, et al. Dupilumab response onset and durability in patients with severe CRSwNP. J Allergy Clin Immunol. 2024;154(6):1442-9. https://doi.org/10.1016/j.jaci.2024.07.026

20. De Corso E, Pasquini E, Trimarchi M, La Mantia I, Pagella F, Ottaviano G, et al. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL). Allergy. 2023;78(10):2669-83. https://doi.org/10.1111/all.15772

21. Lee SE, Hopkins C, Mullol J, Msihid J, Guillemin I, Amin N, et al. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies. Allergy. 2022;77(7):2211-21. https://doi.org/10.1111/all.15222

22. Mullol J, Laidlaw TM, Bachert C, Mannent LP, Canonica GW, Han JK, et al. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials. Allergy. 2022;77(4):1231-44. https://doi.org/10.1111/all.15067

23. Hopkins C, Han JK, Fokkens W, Wagenmann M, Guyot P, Khan AH, et al. Dupilumab Versus mepolizumab for for Chronic Rhinosinusitis With Nasal Polyposis: An indirect treatment comparison. J Allergy Clin Immunol Pract. 2024;12(12):3393-3401.e15. https://doi.org/10.1016/j.jaip.2024.09.015

24. Sanofi-Aventis U.S. LLC. DUPIXENT (dupilumab) injection [Internet]. FDA Highlights of Prescribing Information. Disponible en: www.fda.gov/medwatch.

25. Chhiba KD, Patel GB, Peters AT. Anti-IgE therapy in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2025;155(1):24-30. https://doi.org/10.1016/j.jaci.2024.11.011

26. Gevaert P, Saenz R, Corren J, Han JK, Mullol J, Lee SE, et al. Long-term efficacy and safety of omalizumab in an open-label extension. J Allergy Clin Immunol. 2022;149(3):957–65.e3. https://doi.org/10.1016/j.jaci.2021.07.045

27. Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595-605. https://doi.org/10.1016/j.jaci.2020.05.032

28. Damask C, Chen M, Holweg CTJ, Yoo B, Millette LA, Franzese C. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis. Am J Rhinol Allergy. 2022;36(1):135-41. https://doi.org/10.1177/19458924211030486

29. Gevaert P, Mullol J, Scadding G, Han JK, Canonica GW, Bachert C, et al. Omalizumab in CRSwNP regardless of allergic status. Ann Allergy Asthma Immunol. 2024 Mar;132(3). [Revisar, aparece esta publicación, pero los nombres de autores no coinciden: https://pubmed.ncbi.nlm.nih.gov/37951571/] Gevaert P, Mullol J, Saenz R, Ko J, Steinke JW, Millette LA, Meltzer EO. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status. Ann Allergy Asthma Immunol. 2024 Mar;132(3):355-362.e1. doi: 10.1016/j.anai.2023.11.001

30. Aldajani A, Alroqi A, Alromaih S, Aloulah MO, Alsaleh S. Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review. Am J Otolaryngol. 2022;43(6):103615. https://doi.org/10.1016/j.amjoto.2022.103615

31. Wu Q, Yuan L, Qiu H, Wang X, Huang X, Zheng R, et al. Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a Systematic review and meta-analysis. BMJ Open. 2021;11(9):e047344. https://doi.org/10.1136/bmjopen-2020-047344

32. DailyMed. XOLAIR (omalizumab) injection. U.S. National Library of Medicine [Internet]. Disponible en: https://dailymed.nlm.nih.gov/

33. Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141-53. https://doi.org/10.1016/S2213-2600(21)00097-7

34. Bachert C, Sousa AR, Han JK, Schlosser RJ, Sowerby LJ, Hopkins C, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol. 2022;149(5):1711-21.e6. https://doi.org/10.1016/j.jaci.2021.10.040

35. Fokkens WJ, Mullol J, Kennedy D, Philpott C, Seccia V, Kern RC, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth Sinus surgery analysis. Allergy. 2023;78(3):812-21. https://doi.org/10.1111/all.15434

36. Walter S, Ho J, Alvarado R, Smith G, Croucher DR, Liang S, et al. Mepolizumab decreases tissue eosinophils while increasing type 2 cytokines in eosinophilic chronic rhinosinusit. Clin Exp Allergy. 2022;52(12):1403-13. https://doi.org/10.1111/cea.14152

37. GlaxoSmithKline. NUCALA (mepolizumab) injection [Internet]. Disponible en: www.fda.gov/medwatch

38. Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149(4):1309-17.e12. https://doi.org/10.1016/j.jaci.2021.08.030

39. Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello-Petersen R, Chu DK. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. J Allergy Clin Immunol. 2022;149(4):1286-95. https://doi.org/10.1016/j.jaci.2021.09.009

40. Kim SL, Rank MA, Peters AT. The chronic rhinosinusitis practice parameter. Ann Allergy Asthma Immunol. 2023;131(3):307-10. https://doi.org/10.1016/j.anai.2022.12.022

41. Canonica GW, Harrison TW, Chanez P, Menzella F, Louis R, Cosio BG, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. 2022;77(1):150-61. https://doi.org/10.1111/all.14902

42. Wang Q, Sun Q, Chen Q, Li H, Liu D, Wu Q. Efficacy and Safety of Anti-IL-5 therapies in Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and meta-analysis of Randomized Controlled Trials. Int Arch Allergy Immunol. 2022;183(7):732-43. https://doi.org/10.1159/000521859

43. Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, et al. Effects of Reslizumab on asthma Outcomes in a Subgroup of Eosinophilic Asthma patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2019;7(2):589-96.e3. https://doi.org/10.1016/j.jaip.2018.08.021

44. Wu J, Jones N, Chao PH, Chan V, Hohenwarter L, Wu A, et al. Intranasal delivery of low-dose anti-CD124 antibody enhances treatment of chronic rhinosinusitis with nasal polyps. Biomaterials. 2024;308:122567. https://doi.org/10.1016/j.biomaterials.2024.122567

45. Striz I, Golebski K, Strizova Z, Loukides S, Bakakos P, Hanania NA, et al. New insights into the Pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. Clin Sci (Lond). 2023;137(9):727-53. https://doi.org/10.1042/CS20190281

46. Cai S, Xu S, Lou H, Zhang L. Comparison of Different Biologics for Treating Chronic Rhinosinusitis With Nasal Polyps: A Network Analysis. J Allergy Clin Immunol Pract. 2022;10(7):1876-86.e7. https://doi.org/10.1016/j.jaip.2022.02.034

47. Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C, et al. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2021;3(3):CD013513. https://doi.org/10.1002/14651858.CD013513

48. Lipworth BJ, Greig R, Chan R, Kuo CR. Reappraisal of Biologic efficacy from Phase 3 Trials in Refractory Chronic Rhinosinusitis and Nasal Polyps. J Allergy Clin Immunol Pract. 2025;13(8):1943-51. https://doi.org/10.1016/j.jaip.2025.04.043

49. Rank MA, Chu DK, Bognanni A, Oykhman P, Bernstein JA, Ellis AK, et al. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2023;151(2):386-98. https://doi.org/10.1016/j.jaci.2022.10.026

50. Kratchmarov R, Dharia T, Buchheit K. Clinical efficacy and Mechanisms of biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2025;155(5):1401-10. https://doi.org/10.1016/j.jaci.2025.03.011

51. Lipworth BJ, Han JK, Desrosiers M, Hopkins C, Lee SE, Mullol J, et al. Tezepelumab in Adults with severe Chronic Rhinosinusitis with Nasal Polyps. N Engl J Med. 2025;392(12):1178-88. https://doi.org/10.1056/NEJMoa2414482

52. Ciofalo A, Loperfido A, Baroncelli S, Masieri S, Bellocchi G, Caramia R, et al. Comparison between clinical and cytological findings in chronic rhinosinusitis with nasal polyps treated with Dupilumab. Eur Arch Otorhinolaryngol. 2024;281(12):6511-21. https://doi.org/10.1007/s00405-024-08958-6